Akebia Therapeutics, Inc. — Form D/A
Akebia Therapeutics, Inc. of CINCINNATI, OH, a company, filed a Form D amendment with the SEC on 2011-04-21. The offering totals $22.1M, of which $13.9M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2011-04-21
- Form: D/A
- Accession: 0001517022-11-000002
- Industry: Biotechnology
- Exemptions: 06
- Total offering: $22.1M
- Amount sold: $13.9M
- Remaining: $8.2M
- Minimum investment: $9K
- Investors: 24
- Date of first sale: 2011-04-06
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-158098
Issuer
- Name: Akebia Therapeutics, Inc.
- CIK: 0001517022
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2007
- Address: 9987 CARVER ROAD, SUITE 420, CINCINNATI, OH, 45242
- Phone: 513-985-1920
Officers, directors & promoters (9)
| Name | Role | Location |
|---|
| Anupam Dalal | Director | MORRISTOWN, NJ |
| Joseph Gardner | Director | Cincinnati, OH |
| Campbell Murray | Director | NOVATO, CA |
| John Rice | Director | Bethesda, MD |
| Paul Weiss | Director | Milwaukee, WI |
| Joseph Gardner | Executive Officer | Cincinnati, OH |
| Ian Howes | Executive Officer | Seattle, WA |
| Kevin Peters | Executive Officer | Cincinnati, OH |
| Robert Shalwitz | Executive Officer | Columbus, OH |
Other filings by this issuer (1)
More